{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:22:28Z","timestamp":1794576148427,"version":"4.9.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.curtheres.2026.100839","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:30:09Z","timestamp":1783524609000},"page":"100839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Treatment satisfaction and patient preference for efanesoctocog alfa over previous hemophilia A treatment: Results from the XTEND-1 phase 3 clinical trial"],"prefix":"10.1016","volume":"105","author":[{"given":"Emil","family":"Spasov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Quon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Fukutake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Willemze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Palmborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Kragh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Gerard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-5855","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Msihid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.curtheres.2026.100839_bib0001","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"issue":"Suppl 6","key":"10.1016\/j.curtheres.2026.100839_bib0002","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/hae.13449","article-title":"Joint disease in haemophilia: pathophysiology, pain and imaging","volume":"24","author":"van Vulpen","year":"2018","journal-title":"Haemophilia"},{"issue":"Suppl 6","key":"10.1016\/j.curtheres.2026.100839_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.curtheres.2026.100839_bib0004","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40271-019-00374-x","article-title":"Exploring the impact of infusion frequency in hemophilia A: exit interviews with patients participating in BAY 94-9027 extension studies (PROTECT VIII)","volume":"12","author":"Wells","year":"2019","journal-title":"Patient"},{"key":"10.1016\/j.curtheres.2026.100839_bib0005","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/a-1424-7900","article-title":"Nonfactor therapies: new approaches to prophylactic treatment of haemophilia","volume":"41","author":"Chowdary","year":"2021","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.curtheres.2026.100839_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101164","article-title":"Nothing short of a revolution: novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A","volume":"64","author":"Abdelgawad","year":"2024","journal-title":"Blood Rev"},{"key":"10.1016\/j.curtheres.2026.100839_bib0007","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jtha.2024.04.010","article-title":"Ultra-long factor VIII: a major step forward toward a hemophilia-free mind","volume":"22","author":"Hermans","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.curtheres.2026.100839_bib0008","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1111\/hae.14137","article-title":"Patient and caregiver preferences for haemophilia A treatments: a discrete choice experiment","volume":"26","author":"Su","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.curtheres.2026.100839_bib0009","first-page":"1687","article-title":"Patient and parent preferences for characteristics of prophylactic treatment in hemophilia","volume":"9","author":"Furlan","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.curtheres.2026.100839_bib0010","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2019-126774","article-title":"Patients\u2019 and caregivers\u2019 preferences for different hemophilia A treatment attributes","volume":"134","author":"Joshi","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.curtheres.2026.100839_bib0011","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/hae.14304","article-title":"Patients' and parents' satisfaction with, and preference for, haemophilia A treatments: a cross-sectional, multicentre, observational study","volume":"27","author":"Park","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.curtheres.2026.100839_bib0012","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40267-022-00967-x","article-title":"Treatment satisfaction and limitations in haemophilia A, with a focus on factor VIII product storage conditions: patients\u2019 perspectives and challenges","volume":"39","author":"Zupan","year":"2023","journal-title":"Drugs Ther Perspect"},{"key":"10.1016\/j.curtheres.2026.100839_bib0013","unstructured":"ALTUVIIIO [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] highlights of prescribing information. 2024. https:\/\/www.fda.gov\/media\/165594\/download. Accessed 16 December 2024."},{"key":"10.1016\/j.curtheres.2026.100839_bib0014","unstructured":"ALTUVOCT (efanesoctocog alfa) summary of product characteristics 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/altuvoct-epar-product-information_en.pdf. Accessed 16 December 2024."},{"key":"10.1016\/j.curtheres.2026.100839_bib0015","unstructured":"Pharmaceuticals and Medical Devices Agency. Review Report: Ortzbyo for Intravenous Injection 250, 500, 1000, 2000, 3000 and 4000; efanesoctocog alfa (genetical recombination). Tokyo: PMDA. 2023. https:\/\/www.pmda.go.jp\/PmdaSearch\/rdDetail\/iyaku\/6343459D1028_1?user=1 Accessed 26 May 2026."},{"key":"10.1016\/j.curtheres.2026.100839_bib0016","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.curtheres.2026.100839_bib0017","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa2312611","article-title":"Efanesoctocog alfa prophylaxis for children with severe hemophilia A","volume":"391","author":"Malec","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.curtheres.2026.100839_bib0018","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1477-7525-7-36","article-title":"Validation of an abbreviated treatment satisfaction questionnaire for medication (TSQM-9) among patients on antihypertensive medications","volume":"7","author":"Bharmal","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.curtheres.2026.100839_bib0019","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.clinthera.2024.09.010","article-title":"Patient experience with efanesoctocog alfa for severe hemophilia A: results from the XTEND-1 phase 3 clinical study exit interviews","volume":"46","author":"DiBenedetti","year":"2024","journal-title":"Clin Ther"},{"key":"10.1016\/j.curtheres.2026.100839_bib0020","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1182\/blood.2019001292","article-title":"BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice","volume":"135","author":"Seth Chhabra","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.curtheres.2026.100839_bib0021","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12601","article-title":"The impact of extended half-life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B","volume":"5","author":"Sun","year":"2021","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X26000202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X26000202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:24:01Z","timestamp":1794572641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X26000202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":21,"alternative-id":["S0011393X26000202"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2026.100839","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment satisfaction and patient preference for efanesoctocog alfa over previous hemophilia A treatment: Results from the XTEND-1 phase 3 clinical trial","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2026.100839","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100839"}}